Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

The ENESTfreedom trial assessed the feasibility of treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) following frontline nilotinib treatment. Results for long-term outcomes after a 5-year follow-up are presented herein. Patients who had received ≥2 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Radich, Jerald P., Hochhaus, Andreas, Masszi, Tamás, Hellmann, Andrzej, Stentoft, Jesper, Casares, María Teresa Gómez, García-Gutiérrez, J. Valentín, Conneally, Eibhlin, le Coutre, Philipp D., Gattermann, Norbert, Martino, Bruno, Saussele, Susanne, Giles, Francis J., Ross, David M., Aimone, Paola, Li, Sai, Titorenko, Ksenia, Saglio, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102196/
https://www.ncbi.nlm.nih.gov/pubmed/33707652
http://dx.doi.org/10.1038/s41375-021-01205-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102196/
https://www.ncbi.nlm.nih.gov/pubmed/33707652
http://dx.doi.org/10.1038/s41375-021-01205-5

Ejemplares similares